GSK reports encouraging early Ris-Rez data in small-cell lung cancer
+3 new sources since this summary was written
On 18 October 2026, GSK reported global phase Ib results for investigational risvutatug rezetecan in relapsed extensive-stage small-cell lung cancer. The drug produced a 61% objective response rate at 8 mg/kg among evaluable patients, versus 32% at 6 mg/kg. GSK said the findings support use of the higher dose in the ongoing global phase III EMBOLD SCLC-301 study, with further data due at ESMO Congress 2026.
Why it matters
The 8 mg/kg regimen is now being taken forward in a global phase III study, moving Ris-Rez toward a potentially registrational test in relapsed extensive-stage small-cell lung cancer. The reported safety data will remain relevant as development advances, particularly because higher-dose treatment had more grade 3 or higher treatment-related adverse events.
Key facts
- 1The phase Ib dose-optimisation analysis included 50 patients who had received a median of two prior therapies. marketscreener.com
- 2Grade 3 or higher treatment-related adverse events affected 42% of patients at 8 mg/kg and 15% at 6 mg/kg. marketscreener.com
- 3Interstitial lung disease occurred in 2% of the overall study population, or 1 out of 50 patients, and the case was grade 2. marketscreener.com
- 4The trial data are scheduled for presentation in a poster session at the ESMO Congress 2026 in Madrid, Spain. marketscreener.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.